Home › Research › Inflammation and the immune system
Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer's disease
Seo EJ, Fischer N, Efferth T, Efferth T.. Pharmacological research, 2017-11-24
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD) is the most prevalent form of dementia. The exact pathophysiology of this disease remains incompletely understood and safe and effective therapies are required. AD is highly correlated with neuroinflammation and oxidative stress in brain causing neuronal loss.
What this study adds
Evidence grade: Low
This is a narrative review. This review discusses phytochemicals as possible inhibitors of the NF-κB inflammatory pathway, which is proposed as a target for inflammation-based Alzheimer's therapy. It does not report results from a clinical trial, so it cannot yet show whether these compounds treat or prevent Alzheimer's disease in people.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Seo, E. J., Fischer, N., & Efferth, T. (2018). Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer's disease. Pharmacological research. https://doi.org/10.1016/j.phrs.2017.11.030
Vancouver
Seo EJ, Fischer N, Efferth T. Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer's disease. Pharmacological research. 2018. doi:10.1016/j.phrs.2017.11.030. PMID: 29179999.
BibTeX
@article{seo2018-29179999,
author = {Seo, E. J. and Fischer, N. and Efferth, T.},
title = {{Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer's disease}},
journal = {Pharmacological research},
year = {2018},
doi = {10.1016/j.phrs.2017.11.030},
pmid = {29179999},
url = {https://doi.org/10.1016/j.phrs.2017.11.030}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The exact pathophysiology of this disease remains incompletely understood and safe and effective therapies are required.
- AD is highly correlated with neuroinflammation and oxidative stress in brain causing neuronal loss.
- Nuclear factor of activated B-cells (NF-κB) is involved in physiological inflammatory processes and thus representing a promising target for inflammation-based AD therapy.
- Phytochemicals are able to interfere with the NF-κB pathway.
Why it matters
This review discusses phytochemicals as possible inhibitors of the NF-κB inflammatory pathway, which is proposed as a target for inflammation-based Alzheimer's therapy. It does not report results from a clinical trial, so it cannot yet show whether these compounds treat or prevent Alzheimer's disease in people.
Study details
- Evidence strengthLow
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Pharmacological research) |
| Journal's citation record | 2 / 4 | Pharmacological Research: journal h-index 222 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 265 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 26.5 citations a year over 10 year(s) since 2018 |
| Impact for its field and year | 4 / 6 | Cited 11.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 3 / 4 | Cited 71 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Thomas Efferth: h-index 110 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Johannes Gutenberg University Mainz: institution h-index 934 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 29179999) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Inflammation and the immune system from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.